<DOC>
	<DOC>NCT01464047</DOC>
	<brief_summary>The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Sprycel® so that the regulatory authority can manage the marketing approval properly.</brief_summary>
	<brief_title>Korean Post-marketing Surveillance for Sprycel®</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Newly diagnosed with Philadelphia chromosomepositive (Ph+) chronic myeloid leukemia (CML) in chronic phase Adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including Imatinib Adults with Philadelphia chromosomepositive acute lymphoblastic leukemia (Ph+ALL) with resistance or intolerance to prior therapy According to Warning/Caution in local label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>